Childrens Research Institute, operating under the name Children's National Research Institute, is located in Washington, DC. The organization was established in 1990. According to its NTEE Classification (H98) the organization is classified as: Pediatrics Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Children's National Research Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 06/2022, Children's National Research Institute generated $79.6m in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 5.1% each year. All expenses for the organization totaled $109.0m during the year ending 06/2022. While expenses have increased by 3.8% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
CHILDREN'S NATIONAL RESEARCH INSTITUTE CONDUCTS AND PROMOTES TRANSLATIONAL AND CLINICAL MEDICAL RESEARCH AND EDUCATION PROGRAMS THAT LEAD TO IMPROVED UNDERSTANDING, PREVENTION, TREATMENT, AND CARE OF CHILDHOOD DISEASES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
CENTER FOR NEUROSCIENCE RESEARCH (CNR) - SEE SCHEDULE O.PROGRAM SERVICE ACTIVITY 1CENTER FOR NEUROSCIENCE RESEARCH (CNR): THE CNR HAS GROWN RAPIDLY IN THE PAST 10 YEARS WITH SIGNIFICANT INCREASES IN THE PROGRAM AND THE GENERATION OF IMPORTANT SCIENTIFIC DISCOVERIES. THE CNR CURRENTLY COMPRISES 50 FACULTY MEMBERS WITH FULL APPOINTMENTS AT OUR ACADEMIC AFFILIATE, THE GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES (GW). IN RECOGNITION OF THESE ACCOMPLISHMENTS, CNMC CONSTRUCTED A NEW FLOOR OF LABORATORY SPACE IN 2008 TO SERVE AS HOME FOR THE CNR AND TO PROVIDE ADDITIONAL SPACE FOR RECRUITMENTS. THE CNR CURRENTLY RESIDES IN OVER 12,000 SQUARE FEET OF OPEN ARCHITECTURE RESEARCH SPACE. WE BELIEVE THAT THE CNR IS NOW UNIQUELY POISED TO ACCOMPLISH ITS MISSION, AS ITS RESEARCH PROGRAM, RESEARCH LABS, AND SUPPORTING INFRASTRUCTURES ARE NOW PHYSICALLY LOCATED ON THE 6TH FLOOR OF THE MAIN BUILDING OF CNMC. THIS ALLOWS CLOSE INTERACTIONS BETWEEN BASIC NEUROSCIENTISTS, TRANSLATIONAL NEUROSCIENTISTS, AND CLINICIAN NEUROSCIENTISTS, INCLUDING CHILD NEUROLOGISTS, NEONATOLOGISTS, AND CRITICAL CARE PEDIATRICIANS. THIS UNIQUE AND EXCITING SETTING HAS SUPPORTED AND PROMOTED A LARGE NUMBER OF RESEARCH PROJECTS THAT SPAN BASIC, TRANSLATIONAL AND CLINICAL RESEARCH IN NEURODEVELOPMENTAL DISORDERS. THE CNR INCLUDES EIGHT MAJOR AREAS OF RESEARCH, INCLUDING NEURAL STEM CELLS AND DEVELOPMENTAL NEUROBIOLOGY, BRAIN INJURY AND BRAIN PROTECTION, PERINATAL HYPOXIA AND HYPEROXIA, EPILEPSY, NEURO-ONCOLOGY, NEUROFIBROMATOSIS, ATTENTION DEFICIT HYPERACTIVITY DISORDER, AND AUTISM. THE CNR COMPRISES AN EXPANDING GROUP OF HIGHLY PRODUCTIVE LAB-BASED DEVELOPMENTAL NEUROSCIENTISTS, ALL OF WHOM HAVE ESTABLISHED STRONG RESEARCH PROGRAMS AND COLLABORATIONS IN THE AREA OF NEURODEVELOPMENTAL DISORDERS. WHILE THESE INVESTIGATORS HAVE DISTINCT EXPERTISE AND RESEARCH PROGRAMS, THEIR RESEARCH AS A WHOLE IS FOCUSED ON CHILDHOOD NEUROLOGICAL DISORDERS, FROM EARLY STAGES OF WHEN THE NERVOUS SYSTEM IS FIRST ESTABLISHED, TO POSTNATAL STAGES THAT INCLUDE THE FORMATION OF NEURONAL CONNECTIONS AND THE WRAPPING OF NEURONAL PROCESSES BY THE MYELIN INSULATOR. THUS, INVESTIGATORS AT THE CNR HAVE A COMMON GOAL FOR WHICH THEY ARE ALL STRIVING. THE CENTER FOR NEUROSCIENCE RESEARCH HAD $23,212,607 IN EXPENSES FY 2022.
CENTER FOR GENETIC MEDICINE RESEARCH: THE CENTER FOR GENETIC MEDICINE RESEARCH RESEARCHES, DIAGNOSES, AND TREATS GENETIC DISORDERS-DISEASES AND CONDITIONS IN CHILDREN THAT ARE CAUSED BY INHERITED GENES THAT DO NOT FUNCTION NORMALLY. FOUNDED IN 1999, THE CENTER EMPHASIZESTRANSLATIONAL RESEARCH (BENCH-TO-BEDSIDE) AND HARNESSES EMERGING TECHNOLOGIES FOR GENETIC AND PROTEOMIC ANALYSIS.RESEARCHERS AT THE CENTER FOR GENETIC MEDICINE RESEARCH CONDUCT BASIC AND CLINICAL RESEARCH INTO SOME OF CHILDHOOD'S MOST WELL-KNOWN GENETIC DISORDERS, INCLUDING ASTHMA AND LUNG DISEASE, DIABETES, INBORN ERRORS OF METABOLISM, MACULAR DEGENERATION, MUSCULAR DYSTROPHIES, SICKLE CELL DISEASE, OBESITY & METABOLIC SYNDROME AND WHITE MATTER DISEASE.ALMOST ALL OF THE CENTER'S PROGRAMS COMBINE BASIC, CLINICAL, AND/OR COMMUNITY RESEARCH, INCLUDING STUDIES OF: MUSCLE PHYSIOLOGY, GENETICS, & METABOLISM AND DUCHENNE MUSCULAR DYSTROPHY. THE CENTER FOR GENETIC MEDICINE RESEARCH HAD $17,706,730 IN EXPENSES FY 2022.SHEIKH ZAYED INSTITUTE (SZI) FOR PEDIATRIC SURGICAL INNOVATION: LAUNCHED IN SEPTEMBER 2009, THE RESEARCH SPACE OFFICIALLY OPENED IN APRIL 2011. THE SHEIKH ZAYED INSTITUTE FOR PEDIATRIC SURGICAL INNOVATION AT CHILDREN'S NATIONAL REDEFINES WHAT IS POSSIBLE IN SURGERY FOR CHILDREN BY COMBINING RESEARCH AND CLINICAL EXPERTISE INTO ONE COLLABORATIVE TEAM. THE INSTITUTE DEVELOPS KNOWLEDGE, TOOLS, AND PROCEDURES THAT BENEFIT CHILDREN IN THE WASHINGTON DC REGION, ACROSS THE COUNTRY, AND AROUND THE WORLD. THE PRIMARY FOCUS IS TO LEARN FROM TODAY'S SURGERIES AND CONDUCT INNOVATIVE RESEARCH BASED ON THAT KNOWLEDGE TO IMPROVE PEDIATRIC SURGERY FOR CHILDREN. EACH YEAR THE SZI FACULTY PUBLISH OVER 90 PEER REVIEWED ARTICLES IN TOP RANKED JOURNALS, MORE THAN 50 NEW PATENTS HAVE FILED TO DATE, AND MORE THAN 10 STARTUP COMPANIES HAVE BEEN ESTABLISHED. ALL FACULTY AT THE SZI NOW HOLD NATIONALLY RECOGNIZED PEER REVIEWED FUNDING. THE SZI HOSTS THE NATIONAL CAPITAL CONSORTIUM FOR PEDIATRIC DEVICES INNOVATION, AN FDA FUNDED PROGRAM (ONE OF THE 8 IN THE COUNTRY), TO SUPPORT PEDIATRIC FOCUSED PRODUCT DEVELOPMENT AND ADVOCACY. THE SHEIKH ZAYED INSTITUTE FOR PEDIATRIC SURGICAL INNOVATION HAD $12,853,207 IN EXPENSES FY 2022.TOTAL OTHER PROGRAMS:
CENTER FOR TRANSLATIONAL SCIENCE - SEE SCHEDULE O.PROGRAM SERVICE ACTIVITY 2CENTER FOR TRANSLATIONAL SCIENCE: THE CENTER FOR TRANSLATIONAL SCIENCE SUPPORTS THE FULL SPECTRUM OF INVESTIGATORS (FACULTY, TRAINEES, AND STAFF) AT CHILDREN'S NATIONAL WHO ARE PERFORMING PATIENT-CENTERED CLINICAL AND TRANSLATIONAL RESEARCH (CTR), AND HEALTH SERVICES RESEARCH (HSR). THE POOL OF SUCH INVESTIGATORS AT CHILDREN'S IS LARGE AND GROWING, AND THESE INDIVIDUALS APPROACH THEIR WORK WITH A WIDE RANGE OF EXPERIENCE, EXPERTISE, AND SUPPORT. IT HOUSES BOTH LARGE PROGRAMS OF EXTRAMURALLY FUNDED RESEARCH (E.G. THE CLINICAL AND TRANSLATIONAL SCIENCE AWARD (CTSA) FUNDED BY NIH, THE HRSA-FUNDED PEDIATRIC EMERGENCY CARE AND APPLIED RESEARCH NETWORK/PECARN) AND FACULTY WITH LIMITED FUNDING WORKING ON SPECIFIC, LIMITED PROJECTS. THIS GROWING CENTER EXPENSED $20,551,779 IN FY 2022.
CENTER FOR CANCER AND IMMUNOLOGY RESEARCH - SEE SCHEDULE O.PROGRAM SERVICE ACTIVITY 3CENTER FOR CANCER AND IMMUNOLOGY RESEARCH: THE CENTER FOR CANCER & IMMUNOLOGY RESEARCH (CCIR) AIMS TO DEVELOP AND APPLY SCIENTIFIC KNOWLEDGE IN THE AREAS OF CANCER, BLOOD, AND INFECTIOUS AND IMMUNOLOGIC DISORDERS TO ADVANCE PATIENT CARE. THE CCIR WAS REORGANIZED TO INTEGRATE THE CLINICAL AND RESEARCH ENTERPRISES IN ONCOLOGY, INFECTIOUS DISEASE, HEMATOLOGY, ALLERGY, IMMUNOLOGY AND RHEUMATOLOGY IN ORDER TO BE ALIGNED WITH THE CENTER FOR CANCER AND BLOOD DISORDERS (CCBD) AND PROMOTE AND FACILITATE THE CONDUCT OF TRANSLATIONAL RESEARCH. THIS REORGANIZATION HAS NOW RESULTED IN THE ESTABLISHMENT OF 5 SECTIONS:1. CHILDHOOD CANCER2. INFECTIOUS DISEASE3. CANCER IMMUNOLOGY/IMMUNOTHERAPY4. HEMATOLOGY & TRANSFUSION MEDICINE 5. ALLERGY, IMMUNOLOGY, RHEUMATOLOGYTHE NEW STRUCTURE HAS ALLOWED THE CCIR LEADERSHIP TO WORK CLOSELY WITH CCBD LEADERSHIP TO BETTER DEVELOP A STRATEGIC GOAL FOR THE FUTURE, INCLUDING STRATEGIC EXPANSION OF RESEARCH PROGRAMS RATHER THAN OPPORTUNISTIC RECRUITMENTS. A PRIMARY FOCUS FOR THE NEXT 5 YEARS WILL BE TO ESTABLISH A COMPREHENSIVE CANCER CENTER WITH GWU THAT IS POSITIONED TO APPLY FOR NCI DESIGNATION IN 2023. THE CENTER OF CANCER AND IMMUNOLOGY RESEARCH HAD $18,578,244 IN EXPENSES FY 2022.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Kurt D Newman MD Pres/ceo(cnmc); Chairman(cri) | OfficerTrustee | 2 | $0 |
Mary Anne Hilliard Board Secretary | OfficerTrustee | 2 | $0 |
Aldwin Lindsay Evp, CFO & Board Treasurer | OfficerTrustee | 2 | $0 |
Vittorio Gallo PHD Board Vice Chairman From 7/21 | OfficerTrustee | 39 | $0 |
Anthony Sandler MD SVP Center Of Excellence | 9 | $0 | |
Roger Packer MD SVP Center Of Excellence | 1 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Huron Consulting Group Consulting Services | 6/29/17 | $764,564 |
George Washington University Research Services | 6/29/17 | $1,686,381 |
Johns Hopkins University Research Services | 6/29/17 | $457,703 |
Sparks Personnel Services Inc Consulting Services | 6/29/17 | $449,049 |
Childrens Hospital Corporation Research Services | 6/29/17 | $390,144 |
George Washington University Research Services | 6/29/17 | $1,686,381 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $11,738,622 |
Government grants | $54,331,472 |
All other contributions, gifts, grants, and similar amounts not included above | $12,786,090 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $78,856,184 |
Total Program Service Revenue | $428,709 |
Investment income | $0 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $312,100 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $79,596,993 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $596,267 |
Compensation of current officers, directors, key employees. | $5,247 |
Compensation to disqualified persons | $46,126 |
Other salaries and wages | $51,797,959 |
Pension plan accruals and contributions | $21,379 |
Other employee benefits | $3,947,421 |
Payroll taxes | $2,791,099 |
Fees for services: Management | $52,438 |
Fees for services: Legal | $303,910 |
Fees for services: Accounting | $0 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $14,776,905 |
Advertising and promotion | $58,082 |
Office expenses | $855,278 |
Information technology | $999,622 |
Royalties | $0 |
Occupancy | $650,553 |
Travel | $535,061 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $253,809 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $2,249,883 |
Insurance | $57,789 |
All other expenses | $1,321,899 |
Total functional expenses | $109,045,054 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $0 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $8,896,983 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $0 |
Net Land, buildings, and equipment | $8,170,823 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $17,067,806 |
Accounts payable and accrued expenses | $2,772,974 |
Grants payable | $0 |
Deferred revenue | $12,389,762 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $392,745,237 |
Total liabilities | $407,907,973 |
Net assets without donor restrictions | -$390,840,167 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $17,067,806 |